On September 3, 2025 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada (Press release, C4 Therapeutics, SEP 3, 2025, View Source [SID1234655721]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IMS Annual Meeting 2025 Oral Presentation
Title: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Presentation Date and Time: Saturday, September 20, 2025 at 11:10 am ET
Session: Future Targets and New Modalities of Therapy
Location: Metro Toronto Convention Centre – South Building, Room 701
Presenter: Binod Dhakal, M.D., M.S., associate professor of medicine, Medical College of Wisconsin, Division of Hematology
C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, which continues to demonstrate a well-tolerated safety profile and compelling response rates. The presentation at the IMS Annual Meeting will include data from all safety and efficacy evaluable MM patients from all dose levels studied in the cemsidomide with dexamethasone cohort in the Phase 1 trial. C4T’s investor webcast will highlight the data from the oral presentation at the IMS Annual Meeting and provide additional detail on the company’s planned next steps of clinical development.
C4T Investor Webcast
C4T will host a webcast on September 20, 2025 at 3 pm ET. To join the webcast, please visit this link or the "Events & Presentations" page of the Investors section on the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived and available following the event. Additionally, following the oral presentation at the IMS Annual Meeting, C4T will share that presentation on its website under the Scientific Presentations and Publications page.